New Zealand markets close in 2 hours 27 minutes
  • NZX 50

    +57.39 (+0.49%)

    +0.0047 (+0.77%)

    +0.0042 (+0.76%)

    +22.60 (+0.28%)
  • ASX 200

    +18.80 (+0.24%)
  • OIL

    -0.20 (-0.25%)
  • GOLD

    +2.20 (+0.09%)

    +39.61 (+0.21%)
  • FTSE

    -7.75 (-0.09%)
  • Dow Jones

    +66.22 (+0.17%)
  • DAX

    -42.20 (-0.22%)
  • Hang Seng

    +96.50 (+0.50%)
  • NIKKEI 225

    -252.50 (-0.65%)

    +0.8180 (+0.86%)

Thermo Fisher (TMO) Opens New Cell Therapy Facility at UCSF

Thermo Fisher Scientific TMO recently opened a cGMP manufacturing facility at the University of California, San Francisco (“UCSF”) Medical Center’s Mission Bay campus. The center will be used to accelerate the development and manufacturing of cell-based therapies for complex and rare diseases, including cancer.

The UCSF partnership, which was announced in 2021, will potentially expedite the development of breakthrough treatments by having scientists, clinicians and patients closer to a manufacturing site.


As part of Thermo Fisher’s global pharma services - supporting cell and gene therapies, the UCSF facility will be initially used in treatments for glioblastoma, multiple myeloma and other cancers using updated approaches to CAR-T and CRISPR technologies.

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research


In the new unit, the company offers its customers a range of services for advanced therapies. These include process and analytical development capabilities, clinical and commercial manufacturing services and drug development capabilities from discovery to the commercialization phase.

The rapid emergence of Cell therapy within biotechnology promises future therapeutic applications. Per a representative at Thermo Fisher, a record number of cell therapy approvals in the past two years and the consideration of CAR-T therapies as an early treatment option have forged new partnerships and completely transformed clinical care.

Industry Prospects

Per a Research report, the global cell therapy market was valued at $21.6 billion in 2022 and is expected to witness a CAGR of 14.15% by 2030.

The rise in funding for cell therapy clinical studies, the adoption of useful guidelines for cell therapy manufacturing, and the success of novel products are some of the major factors influencing growth in the number of companies in the market.

Recent Developments

Earlier this month, Thermo Fisher Scientific introduced the Thermo Scientific iCAP RQplus ICP-MS Analyzer. It is a new trace elemental analyzer that simplifies everyday analyses in environmental, food, pharmaceutical and industrial testing laboratories.

In the same month, the company introduced the Thermo Scientific µPAC Neo HPLC Columns for proteomics and biopharmaceutical research. The new line of low-flow HPLC columns improves the separation performance and stability of biologically complex samples.

Price Performance

In the past six months, Thermo Fisher has mostly underperformed its industry. TMO shares have increased 8.5% compared with the industry’s rise of 12.7%.

Zacks Rank and Other Key Picks

Thermo Fisher Scientific currently carries a Zacks Rank #2 (Buy).

Some other top-ranked stocks in the overall healthcare sector are Haemonetics Corporation HAE, Catalyst Pharmaceuticals CPRX and Avanos Medical AVNS. Haemonetics and Catalyst Pharmaceuticals each sport a Zacks Rank #1 (Strong Buy), while Avanos Medical has a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Haemonetics’ stock has risen 29.1% in the past year. Earnings estimates for Haemonetics have remained constant at $2.94 in 2023 and $3.29 in 2024 in the past 30 days.

HAE’s earnings beat estimates in all the last four quarters, delivering an average surprise of 10.98%. In the last reported quarter, it reported an earnings surprise of 7.59%.

Estimates for Catalyst Pharmaceuticals’ 2023 earnings have increased from $1.17 to $1.42 in the past 30 days. Shares of the company have increased 102.7% in the past year.

CPRX’s earnings beat estimates in three quarters while beating the same in one, the average surprise being 3.35%. In the last reported quarter, Catalyst Pharmaceuticals delivered an earnings surprise of 4.76%

Estimates for Avanos Medical’s 2023 earnings have remained constant at $1.68 in the past 30 days. Shares of the company have declined 14.3% in the past year compared with the industry’s fall of 18.2%.

AVNS’ earnings beat estimates in all the trailing four quarters, the average surprise being 11.01%. In the last reported quarter, Avanos Medical delivered an earnings surprise of 25%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report

Haemonetics Corporation (HAE) : Free Stock Analysis Report

Catalyst Pharmaceuticals, Inc. (CPRX) : Free Stock Analysis Report

AVANOS MEDICAL, INC. (AVNS) : Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research